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Retinoblastoma genees, Polyoma virus, Simian Vacuolating Virus 40, the Papilloma viruses and the
human Adenoviruses, were ﬁrst described during a period of intense virus discovery (1930–1960s) and
shown to produce tumors in animals. In each of these cases the viral DNA was shown to persist (commonly
integrated into a host chromosome) and only a selected portion of this DNA was expressed as m-RNA and
proteins in these cancers. The viral encoded tumor antigens were identiﬁed and shown to be required to both
establish the tumor and maintain the transformed cell phenotype. The functions of these viral tumor
antigens were explored and shown to have common features and mechanisms even though they appear to
have evolved from diverse genes. The SV40 large tumor antigen, the human Papilloma virus E7 protein and
the Adenovirus E1A protein were shown to bind to and inactivate the functions of the Retinoblastoma
proteins in transformed cells. This resulted in the activation of the E2F and DP transcription factors and the
entry of cells into the S-phase of DNA synthesis which was required for viral DNA replication. These events
triggered the activation of p53 which promotes apoptosis of these virus infected cells limiting virus
replication and tumor formation. These viruses responded by evolving and producing the SV40 large tumor
antigen, the human Papilloma virus E6 protein and the Adenovirus E1b-55Kd protein which binds to and
inactivates the p53 functions in both the infected cells and transformed cells. Some of the human Papilloma
viruses and one of the Polyoma viruses have been shown to cause selected cancers in humans. Both the p53
tumor suppressor gene, which was uncovered in the studies with these viruses, and the retinoblastoma
protein, have been shown to play a central role in the origins of human cancers via both somatic and germ
line mutations in those genes.
© 2008 Elsevier Inc. All rights reserved.Just as the last half of the twentieth century hosted the explosion of
molecular biology (Watson and Crick, 1953) and steered biology into
many new directions, so too the last half of the nineteenth century
hosted a new understanding of the causes of infectious diseases and
began a great period of exploration in microbiology. This period began
with Pasteur's experiments destroying the concept of spontaneous
generation of organisms and demonstrating that living organisms
beget others of their species. The cornerstone of this revolution was
the formulation of Koch's postulates as an experimental method to
prove that an organism caused a disease. From the isolation of an
organism in the diseased lesion, to its puriﬁcation by culturing it on
agar in a sterile ﬁeld, to the re-inoculation of the organism into the
animal and its causation of the same disease, Koch deﬁned a proce-
dure that satisﬁed the rules of causation. He rapidly demonstrated the
bacterial causes of anthrax and tuberculosis and best of all, these
bacteria were clearly visible in the light microscopes used at the time.
The work of Pasteur, eliminating spontaneous generation, demon-
strating organism speciﬁc fermentations and developing vaccines;l rights reserved.Koch, his postulates and the use of solid agar substrates and individual
colony isolation; and Lister, the need for a sterile ﬁeld and the use of
limiting dilution to obtain a titer of the organism; set the stage for the
ﬁeld of infectious diseases studied and implemented with great
success in the twentieth century.
It was during this time (1879–1898) that a trio of scientists
following in this same experimental path to identify an infectious
agent, clearly found an infectious agent that failed to be validated by
Koch's postulates, could not be isolated in pure culture and was not
even visible in the light microscope (Lustig and Levine, 1992). Adolf
Mayer, a German scientist working at the Agricultural Experimental
Station inWageningen Holland, studied a disease of tobacco plants, he
named tobacco mosaic disease, and demonstrated that the juice from
infected plant extracts could be used to transmit this disease to
healthy plants (Mayer, 1886). He failed to culture this infectious agent
and in a preliminary description of this work (Mayer, 1882) he
described the agent causing the disease as a “soluble, possibly
enzyme-like contagium” and later said it was “bacterial, but that the
infectious forms have not yet been isolated, nor are their forms and
mode of life known” (Mayer, 1886). Clearly the violation of Koch's
postulates was confusing and it was hard to claim that an experi-
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wrong or at least wrong in certain circumstances. The next step in this
adventurewas taken by Dimitri Ivanovsky, a Russian scientist working
in Saint Petersburg. Studying a tobacco epidemic in the Crimea he
rapidly repeated Mayer's experiment, demonstrating a transmissible
infectious agent but he added one more step, he ﬁltered the sap of an
infected plant through a Chamberland ﬁlter made of unglazed
porcelain. This ﬁlter was ﬁrst made by Charles Chamberland, one of
Pasteur's collaborators, to purify water and it was thought to block the
passage of all known bacteria (its pore size was about 0.1 μm). The
importance of this experiment was that it provided an experimental
technique to identify this new class of infectious agents and indeed
they came to be called “ﬁlterable agents” (Ivanovsky, 1892). The third
scientist to add critical insights to this quandary was Martinus
Beijerinck, a Dutch soil microbiologist who collaborated with Adolf
Mayer at Wageningen. Beijerinck also transmitted the disease using
the sap ﬁltered through a Chamberland ﬁlter (he was unaware at the
time of Ivanovsky's experiments) but he also showed that he could
dilute the solution and it would regain its “strength”, or higher titer,
after injection into healthy growing plants, but not while it remained
in solution (Beijerinck, 1898). Thus the ﬁlterable agent could
reproduce itself, and so it was not a soluble toxin produced by a
bacterium, but it did so only in living tissues and not on agar dishes.
These three scientists described an infectious agent that was smaller
than a bacteria (ﬁlterable and not observed in the light microscope)
and was unable to replicate itself outside of a living tissue or its' host
cell. This challenge to Koch's postulates and the science of the day, by
an agent too small to observe, whose only clear property or phenotype
was the transmission of a reproducible disease, must have led to an
uneasy feeling or at least a vague concept of what they were dealing
with. One can see this in the name Bejerinick gave to this agent;
“contagium vivium ﬂuidum” (Beijerinnck, 1898) or a contagious living
liquid.
The DNA tumor viruses
These initial observations were rapidly followed up by other virus
hunters. In 1898 Loefﬂer and Frosch isolated the ﬁrst ﬁlterable animal
virus, the foot and mouth disease virus and in 1901 Walter Reed and
his colleagues uncovered the ﬁrst human virus (which was really a
monkey virus transmitted to humans), yellow fever virus. The next
sixty years (and it continues to this day) uncovered a long list of viral
agents from bacterial, plant and animal hosts (Levine, 1996). The ﬁrst
viruses that caused cancers were identiﬁed by Ellerman and Bang
(1908), who isolated an RNA leukemia virus and Rous (1911) who
isolated an RNA containing sarcoma virus. The ﬁrst DNA tumor viruses
to be isolated were found by Richard Shope. He was ﬁnding tumors in
wild rabbits and in 1932 he isolated the rabbit ﬁbroma virus
demonstrating that ﬁlterable extracts of tumors caused benign
ﬁbromatosis tumors in healthy rabbits injected with these extracts.
One year later Shope reported (Shope and Hurst, 1933) a second virus
of rabbits, the Shope Papilloma virus, which also could produce benign
papillomas inwild rabbits but when the ﬁlterable extract of the tumor
was used to inoculate domestic rabbits (a different species of rabbit)
the virus produced malignant carcinomas (Rous and Beard, 1934;
Syverton and Berry, 1935). Furthermore it was no longer possible to
isolate the infectious viruses from extracts of the malignant tumors of
these domestic rabbits. These early observations, that a virus isolated
from one species could produce malignant tumors in a second species
and the viral agent could no longer be isolated in an infectious form
from these tumors (due to the integration of the virus into the cellular
DNA) was to become a standard paradigm in the DNA tumor virus
ﬁeld. In more recent times the study of the human papilloma viruses,
found ﬁrst inwarts, suffered from the inability to grow these viruses in
cell culture. However the cloning of the genomes of now more than
one hundred human papilloma viruses has uncovered their role bothin benign and malignant diseases. The role of these viruses in the
origins of human genital warts and cancers such as cervical cancer is
now well established and a vaccine that prevents these diseases is
available (see Howley, Galloway, Munger and DiMaio this volume).
The other group of Papovaviruses, the polyomaviruses, was ﬁrst
detected in mice by Ludwig Gross and then Bernice Eddy (Gross, 1953;
Stewart et al., 1958). The virus was named polyoma virus because of its
unusual property of causing tumors of multiple tissues and organs.
This was rapidly followed by the isolation of the SV40 virus in a most
unusual and dramatic fashion. By 1961 the Salk polio vaccine was
being produced by four companies in accordance with the rules of the
Public Health Service for Biological Products; “virusmaterial grown on
normal cells inactivated by formalin is acceptable” (Provost and
Hilleman, 1979). These restrictions meant that the cells used for the
replication of poliovirus for vaccine production came from the normal
kidney cells of monkeys and the most abundant source of cells came
from the rhesus and cynomolgus monkeys in India. These monkeys
were trapped all over India and shipped to two central airports for
export where they were housed in gang cages containing many
animals. This was an infectious disease nightmarewhere viruses could
spread from one animal to another and even from humans to
monkeys. Maurice Hilleman who was producing an inactivated polio
vaccine for Merck appreciated this problem and got good advice from
William Mann, the director of the Washington D.C. Zoo. Mann
suggested that Hillman obtain his monkeys from Africa, where there
was a large number of African Green Monkeys (AGMK) and ship them
through Madrid where no other primates were housed to avoid more
virus contamination. Hilleman determined that poliovirus replicated
well in AGMK cells. As a test to determine that the poliovirus was
inactivated by this treatment, he placed the formalin inactivated
poliovirus vaccine, which did not grow in rhesus cells and was
inactivated, onto these AGMK cells. Surprisingly he saw the cytopathic
effects of a virus in the vaccine extract that had been made in rhesus
cells. The rhesus cells themselves harbored a virus that had no
cytopathic effects in rhesus and that failed to be inactivated by the
formalin treatment that killed the polio virus, and this new virus,
whichwas named Simian Vacuolating Virus 40 or SV40, replicated and
killed AGMK cells. As Hilleman stated in his publication about this
surprising result; “The discovery of this new virus, the vacuolating
agent, represents the detection for the ﬁrst time of a hither-to
“nondetectable” simian virus of monkey renal cultures and raises the
important question of the existence of other such viruses” (Sweet and
Hilleman, 1960). Antibodies directed against SV40 could be detected
in ﬁve of seven children who received the Salk vaccine (Sweet and
Hilleman, 1960). In the wild only about 10% of rhesus monkeys have
SV40 antibodies but after a stay in the gang cages in India and upon
arrival in the United States 69% of the monkeys had SV40 antibodies
(Meyer et al., 1962).
Maurice Hilleman at Merck and Bernice Eddy at the NIH began to
study this new SV40 virus. Eddy was able to show that an injection of
an extract of rhesus monkey kidney cells into new born hamsters
would cause tumors in these animals (Eddy et al., 1961). By the
following year Hillemans' group (Girardi et al., 1962) and Eddy's team
(Eddy et al., 1962) both showed that the agent that was responsible for
causing these tumors was indeed SV40. While these hamster tumors
contained no infectious virus, they did produce antibodies directed
against a viral protein expressed in the tumor cells, the large tumor or
T-antigen. These tumors in hamsters were found some six to seven
years after the polio vaccine, contaminated with SV40, was licensed
and in use. The vaccine was a great success, in the last three years
(1950 to 1953) before the introduction of the polio vaccine there were
about 21,000 cases of paralytic polio per year in the United States. By
1961 the number of cases fell to 465 and by 1969 only 18 cases were
reported (mostly do to failure to vaccinate). Given that record there
was no reasonable possibility to withdraw the vaccine. Instead the
polio virus was repeatedly plaque puriﬁed on AGMK cells and all
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contained no contaminating SV40 virus. There is today, no credible
evidence (although some virologists dispute this) that SV40 has
caused tumors in humans, although recently a new related polyoma
virus has been identiﬁed in the human population that is associated
with Merkel cell tumors in humans (Feng et al., 2007).
The third member of the small DNA tumor viruses, the Adeno-
viruses, was uncovered in a set of two very different experiments.
Wallace Rowe, working at the NIH in the early 1950s was attempting
to isolate viruses that cause the common cold. At the time it was
popular to remove the adenoids and tonsils from children tominimize
future infections. Rowe was using these human tissues as a source of
tissue culturematerials to isolate other viruses, but he noticed that the
cells growing out of the explant would often replicate for a while then
degenerate and die. Rowe considered the possibility that the adenoid
cells harbored a virus that was activated in culture and killed the cells
and he went on to show (Rowe et al., 1953) this was the case and he
named these new agents the AD viruses (adenoid virus). At the same
timeMaurice Hillemanwas at theWalter Reed Army Institute andwas
sent out to isolate Inﬂuenza viruses from a respiratory epidemic that
was going on at Fort Leonard Wood in Missouri. After collecting
hundreds of samples of throat cultures Hilleman repeatedly failed to
ﬁnd the Inﬂuenza virus but another agent was commonly found in
these samples which he called the RI virus (respiratory illness virus)
(Hilleman and Werner, 1954). It soon became clear that the AD and RI
viruses were closely related strains and Rowe had isolated a group of
Adenoviruses (serotypes 1,2,5,6) which gave rise to persistent
infections while Hilleman had isolated a group (serotypes 3, 4
and 7) of epidemic Adenoviruses. Hilleman went on to attempt to
make an Adenovirus vaccine by growing this virus in monkey cells.
The virus replicated in some monkey cells but not others, and only
later was it appreciated that the Adenoviruses would not produce
infectious viruses in monkey cells unless those cells were co-infected
or contaminated with SV40 (Rapp et al., 1964). Of the nine soldiers
vaccinated with the Adenovirus vaccine strain in the early 1950s, all
nine developed antibodies against the SV40 virus (Sweet and
Hilleman, 1960). Some strains of Adenovirus grown in monkey cells
produced Adenovirus-SV40 recombinant viruses (Ross et al., 1978).
Although it was not appreciated at the time the discoveries of the
small DNA tumor viruses were quite intertwined. A few years later
(Trentin et al., 1962) John Trentin and his colleagues demonstrated
that some of the Adenovirus serotypes (serotype 12) were capable of
initiating tumors in hamsters. As in the case of SV40 and the Papilloma
viruses the animals bearing these tumors made antibodies against a
subset of the viral encoded proteins and those antibodies detected
these viral encoded proteins (Tumor antigens) in the cells of the
tumor. The papilloma viruses, SV40 and the Adenoviruses all produced
different tumor antigen proteins so that these antigens were unrelated
and this permitted one to detect which of these viruses could cause
tumors in a host. Tumor antigens were virus speciﬁc and any one virus
type produced the same tumor antigens independent of the host or
the individual tumor.
Transformation and tumorigenesis by the small DNA
tumor viruses
When infectious Adenoviruses and SV40 form tumors in animals
the cells of the tumor all contain the viral DNA which produces the
tumor antigens but no infectious virus can be isolated from extracts of
those cells. A set of experiments designed to explore the nature of the
viral DNA in tumor cells demonstrated that some or all of the SV40
viral genome was integrated into one of the chromosomes of the host
cell (Sambrook et al., 1968) and only a portion of the Adenovirus
genome was found to be integrated into a host chromosome
(Sambrook et al., 1980). These integration events could occur
randomly into the host genome from tumor to tumor, but all of thecells from a single tumor contained the identical integration site. This
demonstrated that tumors arose clonally from a rare event of virus
infection and transformation. Both in animals (hamsters or mice or
rats) or cells in culture, the highest rates of transformation were
achieved in non-permissive hosts and cells. The transformation of
cells in culture by the DNA tumor viruses was recognized and selected
for by the ability of the virus to change several properties of cell
growth in culture; 1. the ability to immortalize cell growth in culture
so that a permanent cell line is produced, 2. growth of transformed
cells in low (1%) concentrations of serum, 3. growth to high saturation
densities (the number of cells per square cm in a colony or a culture
dish), 4. the growth of cells in agar suspension cultures or anchorage
independence, and 5. the ability to produce a tumor when injected
into an isogenic or immunocompromised animal. After an infection of
non-permissive cells with a virus and the selection of cloned cell lines
with these properties, an integrated viral DNA was commonly
detected in the genome of the transformed clone. However, it was
also possible that spontaneous clones could arise in the absence of
these viral agents with these same transformed cell properties. This
did demonstrate that there were alternative ways to transform a cell.
In tumors and in transformed cells in culture only a selected
portion of the integrated viral genome was found to be expressed as
mRNA's (Botchan et al., 1974; Gallimore, 1974). For SV40 this region
corresponded to the portion of the viral chromosome expressed early
after infection and encoded two proteins, the SV40 large T-antigen
and the small t-antigen (Huebner et al., 1963). For the Adenoviruses
this region corresponds to a subset of the early genes termed the E1A
proteins and the E1B proteins composed of the E1B-55Kd and E1B-
21Kd proteins (Ross et al., 1980a,b). Subsequent experiments with the
human papilloma viruses uncovered a similar set of early proteins
called the E6 and E7 proteins. For example HeLa cells in culture were
derived from a cervical carcinoma of humans some seventy years ago
and these cells still contain an integrated copy of HPV-18, which
expresses both the E6 and E7 genes of the virus in culture, but
produces no infectious virus. If these E6 or E7 gene products are
turned off or inhibited, these cells will no longer replicate in culture. It
was the fear of endogenous virus contamination in human cell
cultures derived from cancers that lead the Public Health Service to
rule that only normal cells (e.g. monkey cells) be used for vaccine
production and not human cancer cells. Thus the tumor antigens
expressed in every tumor cell were identiﬁed and characterized often
employing sera from tumor bearing animals to immunoprecipitate
these proteins and analyze them by SDS-PAGE to characterize these
proteins by their molecular weights.
Two different approaches were used to explore the functions of the
tumor antigens of the small DNA tumor viruses; 1. viral genetics and 2.
DNA transfection of viral genes into cells to determine their ability to
transform these cells. Temperature sensitive mutants of the Polyoma
virus large T-antigen gene were obtained and these mutants failed to
transform cells in culture at the non-permissive temperature. In
addition these viral mutants failed to produce tumors in mice in those
tissues at a high body temperature (internal tissues) but these
mutants could make tumors in tissues with lower temperatures
(skin, etc) (see Roberts, this volume). Similar results were obtained for
the large T antigen of SV40. In a different experimental approach cells
were transformed by this virus at the permissive temperature, but
when these cells were switched to the non-permissive temperature
(inactivating the T-antigen) they reverted to normal cells by all of the
criteria employed for the transformed phenotype (Tegtmeyer, 1975;
Brugge and Butel, 1975; Osborn and Weber, 1975; Martin and Chou,
1975). Thus the SV40 large T-antigen was required for both the
establishment and the maintenance of the transformed phenotype
(similar to HPV 18 E6 and E7 genes in HeLa cells). Similar experiments
have demonstrated that the SV40 small t-antigen is also required to
transform cells in culture (Pipas and Levine, 2001a,b, also see Pipas,
this volume)). Adenovirus mutants in the E1A gene or the E1B genes
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cloned isolated genes of the Adenovirus genome the transforming
properties of the E1A genes and the E1B genes could be separated (see
Branton, this volume). In some cell types it can take two different
oncogenes to fully transform a cell. In rat embryo ﬁbroblasts (REF)
both a myc and a ras oncogene are required to fully transform these
cells (Land et al., 1983). Myc alone will only immortalize these cells
while ras alone will stop the growth of these cells (a phenotype of
senescence) and fail to transform them. Thus myc suppresses or
compensates for the ras senescence phenotype. The E1A gene can act
with ras to fully transform these cells and E1A alone will immortalize
these cells. The E1B gene will act with myc to fully transform these
cells but E1B alone does not transform these cells. Similarly the
Papilloma virus E6 and E7 genes are required together to fully
transform these cells (see Galloway and Munger, this volume). While
the RNA tumor viruses commonly incorporate a cellular oncogene into
their genome and transform cells with it, the DNA tumor viruses have
viral encoded oncogenes in their genome and unlike the RNA tumor
viruses they employ these functions for the duplication of the virus
during productive infection.
In all of these viruses at least two or three separate functions are
required to transform cells in culture and likely produce tumors in
animals. The viral DNA sequences and proteins that carry out these
transforming functions are different for each virus and each viral class.
The papilloma viruses, the polyoma viruses and the adenoviruses
appear to have evolved a set of genes, genomes and functions quite
independently. In addition all of these transforming oncogenes have
clearly evolved to maximize the replication of these viruses (see
Fanning and Botchan, this volume). All of these small DNA viruses face
many of the same hurdles and have the same requirements to
replicate their DNA in cells and produce a maximal level of viruses. It
was during the exploration of the functions of the transforming
proteins that it became clear that there were indeed common features
in the duplication of these viruses and the transformation of cells and
that the needs of replicating these viruses created a set of tumor
viruses.
The functions of the DNA tumor virus tumor antigens and
transforming proteins
The very nature of a small genome size of these DNAviruses means
that they must rely upon their host cells to provide many functions for
virus replication. Each of these viruses has devised methods to place
the infected host cell into a replication cycle and make a resting cell
enter S-phase or initiate DNA replication (Ritzi and Levine, 1970). This
will produce the necessary precursors for DNA replication (ribo- and
deoxyribonucleoside triphosphates) and initiate the synthesis of
enzymes required for viral and cellular DNA replication. Thus with
most of these viruses it was observed that resting cells were induced
to enter a cell cycle of DNA replication and that one of the tumor
antigen (SV40 T-antigen, Adenovirus E1A proteins and Papilloma virus
E7 proteins) accomplished that. Not only was cellular DNA synthesis
induced by the SV40 T-antigen but so were enzymatic activities
employed during DNA replication. Cells contain two enzymatic forms
of thymidine kinase (encoded by two separate genes), one that is
synthesized and active in adult resting cells and one that is found in
actively growing cells of fetuses, regenerating liver and cancer cells
(Postel and Levine, 1974, 1975). A study of these two forms of
thymidine kinase demonstrated that SV40 T-antigen could regulate or
turn on the fetal form or actively growing form of this enzyme (Postel
and Levine, 1976). Similar observations were made with carcinoem-
bryonic antigen in colon cancers and alpha-fetoprotein in liver
cancers. This led to the hypothesis that fetal antigens were re-
expressed in tumors or transformed cell lines and that was controlled
by the viral oncogenes. This idea led Linzer and Levine (1979) to use
sera from hamsters bearing tumors induced by SV40 to determine ifthat sera contained antibodies directed against host proteins
expressed in fetal cells. The source of fetal cells was embryonal
carcinoma cells (fetal tumors), which are the stem cells of terato-
carcinomas of mice and humans. Sera from hamsters carrying SV40
induced tumors did indeed contain antibodies that reacted with a
cellular protein of 53,000 Da inmolecular weight whichwas produced
in these embryonal carcinoma cells (Linzer and Levine, 1979).
Interestingly SV40 transformed cells contained very high levels of
this same p53 protein and most cancer cells in culture contained high
levels of the p53 protein (Linzer and Levine, 1979). In SV40
transformed cells these high levels of p53 were regulated by the
temperature sensitivemutant of the SV40 T-antigen gene (Linzer et al.,
1979) demonstrating that the viral oncogene controlled the levels of
this host protein. Normal cells in culture did express the p53 protein
but at very low levels because the half life of this protein was only
about 20min (Oren et al., 1981). At this same time three other research
groups made similar observations (Lane and Crawford, 1979; DeLeo
et al., 1979; Kress et al., 1979) and Lane and Crawford (1979)
demonstrated that the SV40 large T-antigen formed a protein complex
with the host cell p53 protein. The observation that animals bearing
tumors initiated by the SV40 virus made antibodies against the p53
protein classiﬁed the p53 protein as a tumor antigen. The fact that the
p53 protein increased its' concentration in many different kinds of
cancer cells suggested that p53 could be an oncogene acting to help
transform cells. This idea was reinforced by the research of this era.
The last half of the 1970s and the ﬁrst half of the 1980s was the time of
an intense search for oncogenes in RNA viruses and in cancer cells. It
was clear that there were lots of oncogenes derived from the host cell
that containedmutations that activated these genes so that they could
transform cells and cause tumors. That excitement left p53 and the
DNA tumor viruses on the edge of the real action and only a small
group of scientists worked with p53.
By 1981 to 1983 several research groups had cloned a p53 cDNA
from cells in culture and the sequences were published (Oren and
Levine, 1983). The race was then on to determine if this p53 cDNA
could indeed transform a cell in culture. Several groups published that
the transfection of the p53 cDNA plus the Ras oncogene could indeed
transform REFs in culture and so p53 appeared to be like myc or the
Adenovirus E1A genes, able to immortalize cells and help Ras
transform cells (Eliyahu et al., 1984; Parada et al., 1984; Jenkins
et al., 1984). As it sometimes happens in science one group (Levine
et al., 2004) with a p53 c-DNA clone could not obtain these results and
so had nothing to publish. Interestingly a comparison of the p53 cDNA
clones that could transform cells and the one that did not had a one
amino acid difference at codon 135 (Levine et al., 2004). That of course
could be due to a sequencing error, but if that was not the case, which
was the wild type and which was the mutant form? If one was a
mutant cDNA did it have a phenotype? Did the wild type transform
(like myc) or did the mutant cDNA transform cells (like Ras)? Was it
even possible that this was simply two splice alternatives or a
polymorphism? The Hinds, Finley and Levine team, having a cDNA
that failed to transform cells, and no publication about this negative
result, went to work on these questions (Levine et al., 2004). First
Moshe Oren sent them his transforming p53 cDNA clone and it
became clear that Oren's clone transformed cells and had a valine at
codon 135 and Levine's clone did not transform cells and had an
alanine at codon 135 (Pennica et al., 1984). The sequences of the wild
type mouse gene were shown to contain alanine at codon 135. This
demonstrated that the wild type p53 cDNA clone did not transform
cells but the mutant clone did transform REF cells in culture (Hinds
et al., 1989). Most interestingly mixing a wild type p53 clone with a
mutant p53 clone and Ras, failed to transform REF cells in culture. In
fact the wild type p53 cDNA clone prevented myc plus ras and E1A
plus Ras from transforming REF cells in culture (Finlay et al., 1989).
When upon rare occasions the wild type p53 clone failed to stop
transformation of REF cells by these oncogenes it could be shown that
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phenotype (Finlay et al., 1989). In these experiments thewild type p53
cDNA was acting as a tumor suppressor gene. At this same time the
Vogelstein group demonstrated that three human colon carcinomas
contained mutations in both copies of the p53 gene carried by that
tumor (Baker et al., 1989), providing another line of evidence that p53
was indeed a tumor suppressor gene and not an oncogene. The
mutant form of the p53 protein however could act like an oncogene. In
the experiments that demonstrated that a mutant p53 could trans-
form cells in culture the mutant p53 protein made in those cells
entered into a tetrameric protein complex with the endogenous wild
type p53 proteins, and this poisoned the wild type p53 activity and
function in a cell. Thus the mutant p53 cDNA created a “dominant loss
of function” of wild type p53 in a cell and as such inactivated the wild
type p53 protein. Consistent with these interpretations was the
observation that retroviruses intergrating into the p53 gene (and
creating a mutant p53 gene) and bringing an oncogene into that cell
could initiate a tumor in animals (Munroe et al., 1988; Ben David et al.,
1988). In more recent years a number of groups have provided
increasingly convincing evidence that mutant p53 proteins also have a
true “gain of function” phenotype making tumors more resistant to
chemotherapy resulting in lower overall survivals of patients with p53
mutations (Dittmer et al., 1993; Strano et al., 2000; Blandino et al.,
1999). The mechanisms that mediate this gain of function phenotype
appear to be the ability of a missense mutant p53 protein to combine
with other transcription factors in cells (like p73), alter their
transcriptional proﬁles and make the cell more resistant to apoptosis
(Strano et al., 2000).
Thus from 1979 until the present, the p53 gene and protein has
been called a tumor antigen, an oncogene and a tumor suppressor
gene. The mutant gene and its protein produce phenotypes for both a
“dominant loss of function” and a “gain of function” in transformed
cells. These experiments also forced a reinterpretation of the
observations made in SV40 transformed cells. The SV40 large
T-antigen complex formed with p53 inactivated the functions of the
p53 protein even though it dramatically increases its' concentration in
transformed cells. It was equally clear that the SV40 large T-antigen
was inactivating a potent tumor suppressor gene in tumors and
transformed cells. That themechanisms of transformation by all of the
small DNA tumor viruses could be related received a big boost from
the observation that an Adenovirus oncogene product, the E1B-55Kd
protein was able to form a protein complex with the p53 protein in
virus infected and transformed cells (Sarnow et al., 1982). This too
inactivates the functions of the p53 protein and adds to the ability of
this virus to transform cells and produce tumors in animals. Several
years later Werness et al (1990) demonstrated that the E6 oncogene
products of HPV-16 and 18 (the tumorigenic human PapillomaTable 1





Papilloma virus E7 E6
Each of the small DNA tumor viruses encodes a set of oncogenes which are essential for
the replication of the virus in a cell. One of these oncogene products combines with the
cellular Rb protein releasing the transcription factors E2F-DP which transcribe a set of
genes that produce proteins essential for moving the cell from a resting state into
S-phase or DNA replication. These very same enzyme activities are employed by the
virus to replicate its own DNA in an infected cell. The viral oncogene product (T-antigen,
E1A and E7) that activates cellular and viral DNA synthesis also results in the activation
of p53 and the initiation of an apoptotic signal in the cell. This would limit the ability of
the virus to replicate in these cells. Thus each of these viruses has independently
evolved a second oncogene product (T-antigen, E1B-55Kd, E6) which inactivates the
p53 protein function.viruses) were bound to the p53 protein in HPV transformed cells.
The E6 protein recruited another cellular protein and this resulted in
the poly-ubiquitination of the p53 protein and its rapid degradation in
the proteosome of a transformed cell (Scheffner et al., 1990). Thus
SV40, the Adenoviruses and the tumorigenic Papilloma viruses all
targeted the same cellular protein for inactivationwith their oncogene
products and in so doing eliminated a tumor suppressor activity from
these cells (Table 1). Because the SV40 T-antigen, the Adenovirus E1B-
55Kd and the HPV E6 proteins are completely unrelated in their amino
acid sequences, this is an example of convergent evolution to satisfy a
need that must be required for these viruses to replicate in cells. But
why do these viruses have to inactivate the functions of the p53 tumor
suppressor protein?
When the small DNA tumor viruses enter a cell they transcribe a
portion of their genome, the early region of the genome, expressing
their oncogene products and activities required for the duplication of
viral DNA. The oncogene products initiate a round of cellular DNA
replication so that all of the cellular enzymatic activities that
contribute to DNA replication (synthesis of precursors, DNA poly-
merases, ligases, unwinding proteins etc) are synthesized by the cell.
The genes that encode these proteins used during DNA replication are
transcriptionally regulated by several transcription factors, E2F and
DP, which form a complex and promote the expression of those genes.
The E2F-DP complexes are normally bound to three different
retinoblastoma proteins (Rb) in resting cells, which prevents them
from expressing the gene products required for entry into S-phase
(see DeCaprio, this volume). As cells get external (hormonal) signals to
divide, this results in the synthesis of cyclin D which combines with
the cyclin-dependent kinases, cdk-4/6. These kinases phosphorylate
the Rb proteins which release some of the E2F-DP proteins from this
complex permitting the synthesis of cyclin E. A cyclin E-cdk2 complex
completes the phosphorylation of Rb and the E2F-DP proteins fully
express the genes needed for a cell to enter S-phase. The cyclin D to
cyclin E transition sets up a positive feedback loop that initiates an
autocatalytic entry into S-phase of the cell cycle. During this process
the p53 protein acts to detect stress signals that would introduce
errors into the duplication of these cells. For example if the DNA
template was damaged and this damaged DNA was replicated the
mutation rate in cells increases. Spindle poisons (anuploidy), hypoxia,
nutritional deprivation, heat or cold shock and even oncogene
activation in a cell are all stress signals recognized by p53 and each
of these stresses will introduce a lack of ﬁdelity into the replication
process (Fig. 1). When the p53 protein is activated by a stress signal it
is modiﬁed (phosphorylation, methylation, etc) and increases its
concentration resulting in its ability to transcribe a set of genes that
can respond to these stress signals. One of the genes p53 regulates is
the p21 gene. This produces a protein that binds to cyclin D-cdk 4/6
and inhibits this activity, preventing Rb phosphorylation and pre-
venting the entry into the S-phase. In different circumstances the
activated p53 protein transcribes a program for cell senescence
terminating cell division. Alternatively the activated p53 protein can
roll in a program to initiate apoptosis resulting in programmed cell
death and the elimination of a clone of cells that contains many
mutations and mistakes. This is a major tumor suppressor activity
(Fig. 1).
All of the DNA tumor viruses wish to initiate a high rate of
expression of those cellular functions that force a cell to enter S-phase
and replicate DNA. The viruses can then utilize these DNA precursors
and enzymatic activities to maximize the replication of their own
DNA. They accomplish this by inactivating the functions of the Rb
proteins, releasing E2F-DP transcription factors to bring the cell into
S-phase. The SV40 large T-antigen binds to the Rb protein releasing its
transcription factors just as phosphorylation by cellular activities had
done in an uninfected cell (DeCaprio et al., 1988). The Adenovirus E1a
protein also binds to Rb (Whyte et al., 1988) and the E7 protein of HPV
binds to the cellular Rb protein releasing the E2F-DP transcription
Fig. 1. The p53 pathway. A wide variety of diverse stress signals are detected by and transmit the stress signal to the core p53 regulatory molecules using post-translational
modiﬁcations such as phosphorylation, methylation, acetylation, ubiquitination, summolation and neddylation. These modiﬁcations of p53, MDM-2 and MDM-X result in the
stabilization of p53 by its increased half-life and activation of p53 as a transcription factor. MDM-2 is the ubiquitin ligase for p53 and the MDM-2 gene is a positively regulated
transcriptional target of p53. Thus p53 and MDM-2 form an auto-regulatory loop resulting in the oscillation of these two proteins after the activation of p53 by a stress. MDM-X is
required for the MDM-2 negative regulation of p53 and it is a target for poly-ubiquitination by MDM-2 resulting in a second auto-regulatory loop being formed. MDM-X also can
directly inhibit p53 activity by binding to it. When the Rb protein is inactivated in a cell bymutation or by an oncogene product of the DNA tumor viruses, the E2F transcription factor,
which is freed from the negative regulation by Rb transcribes the ARF gene. The ARF protein binds to theMDM-2 protein and inhibits its poly-ubiquitination of p53. P53 levels rise and
its transcription is activated resulting in apoptosis. For that reason all of the DNA tumor viruses also must inhibit the p53 activity in an infected cell. The detection of many diverse
stress signals often result in the auto-ubiquitination of MDM-2 and poly-ubiquitination of MDM-X. This increases the half-life of the p53 protein and activates it for the transcription
of its target genes. This results in cell cycle arrest, senescence or apoptosis of the cell.
290 Minireviewfactors in virus infected cells (Dyson et al., 1989) (Table 1). Thus all of
the small DNA tumor viruses have evolved the same mechanism to
inactivate the Rb protein and initiate cellular DNA replication so that
these viruses will have the precursors and enzymes required to
produce more viruses. Rb, like p53, is a tumor suppressor gene
regulating the entry of cells into the cell cycle, and the inactivation of
the Rb protein by the oncogenes of the small DNA tumor viruses
makes these viruses tumor viruses. The transforming ability of these
viruses is simply a by product of their need to initiate DNA replication
in the cells they choose to replicate in. But why do these viruses also
need to inactivate the p53 tumor suppressor gene? What is clear is
that virus infection of cells is a stress signal that activates the p53
transcriptional program in an infected cell. When SV40 T-antigen
mutants in the p53 binding site, or Adenovirus mutants in the E1B
55Kd gene or HPV mutants in the E6 gene are employed to infect cells
(so p53 then becomes active) or are introduced into cells with the
remainder of the viral genome intact and wild type, the infected cells
undergo a p53 mediated apoptosis. This is due in part to the
inactivation of Rb and the free high levels of E2F-DP. If high levels of
E2F are present in cells (either due to an Rb mutation or the
introduction of an E2F c-DNA) and p53 is activated, then a p53
mediated apoptosis will occur in those cells (Wu and Levin, 1994). So
an activated p53 protein senses inappropriate high activities of E2F
and kills the virus infected cell, limiting virus replication. Thus it is
clear why the virus must eliminate both Rb and p53 activities so as to
maximize its own replication. But how is p53 activated (modiﬁed and
at an increased concentration so as to roll in a program of cell death) in
a virus infected cell?
The p53 protein in a cell is normally kept at very low concentra-
tions with a very short half life of 8 to 20 min. The ubiquitin ligase that
controls this is called MDM-2 which binds to p53 and poly-
ubiquitinates it. MDM-2 is transcriptionally regulated by p53, so
high levels of p53 result in increased amounts of MDM-2, which
lowers the levels of p53 and this in turn lowers the levels of MDM-2.
This auto-regulatory loop (Wu et al., 1993) forms an oscillator in the
cell which controls p53 and MDM-2 levels permitting very little
variation (Lahav et al., 2004; Hu et al., 2007). Stress signals often
inactivate MDM-2, causing large increases in p53 (with no increased
MDM-2 function) and this results in apoptosis or cell cycle arrest(Fig. 1). When Rb is inactivated by a virus and E2F activity is increased
one of the genes that E2F regulates is a tumor suppressor gene called
ARF. The ARF protein can bind to MDM-2 and decrease its activity
resulting in higher activities of p53 in a cell (Levine et al., 2006).Thus
the inactivation of Rb by either mutation or an oncogene of the small
DNA tumor viruses increases the E2F activity, which produces ARF,
which inactivates MDM-2, which in turn activates p53. This is
obviously a cellular fail safe, creating a signal transduction pathway
with a feedback loop to kill the cell that has activated an oncogene
(E2F), inactivated a tumor suppressor gene (Rb) or sustained an
infection with one of these viruses. Had the DNA tumor viruses not
found a way to inactivate p53 they would not have existed today.
These viruses cause tumors because they had to ﬁnd a way to get cells
to replicate and bypass the fail safes that cells have developed to
prevent an inappropriate entry into S-phase.
There may well be other stress signals that activate p53 in cells
infected with DNA viruses. The DNA replicative intermediates of these
viruses have lots of free ends in the DNA during the replication process
and these newly synthesized molecules look like damaged DNA or
recombination intermediates with DNA breaks. There is a good deal of
evidence that AMP kinase recognizes these “damaged” DNA inter-
mediates and signals to MDM-2 and p53 which then kills these
infected cells. P53 also has the job of preventing abnormal
recombination events which reduces the recombination rates in a
cell, inappropriate translocations, and ampliﬁcations of DNA regions.
Because of these observations it has been speculated that p53 is
inactive or less active during S-phase, in meiotic cells and in B or
T-cells undergoing recombinations of the immunoglobulin genes.
Thus it has been suggested that the DNA replicative intermediates of
the DNA viruses are recognized by the stress alarm system and this
could activate p53 to kill virus infected cells. In either case the p53
pathway is acting much like the innate immune system in attempting
to clear and kill virus infected cells. For that reason successful viruses
have found a way to inactivate the p53 pathway.
Human cancers and the small DNA tumor viruses
Many different human tumors have inactivated both the Rb and
p53 gene by mutations in the somatic cells of a cancer. Indeed about
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alleles (Levine et al., 2006). Individuals that inherit a mutation in one
allele the Rb gene will develop multiple retinoblastomas in both eyes
during childhood and the tumors will have lost the wild type allele
(Knudson, 1971) and in some cases ampliﬁed the MDM-4 gene.
MDM-4 is a close sequence relative to theMDM-2 gene that is required
to degrade p53 protein, so this ampliﬁcation compromises p53
functions in this tumor (Fig. 1). This is just like the DNA tumor
viruses' inactivating both tumor suppressor gene products because
inactivation of Rb activates the p53 activity. Individuals with inherited
p53 mutations (Li-Fraumeni Syndrome) in one allele of this gene
develop a variety of cancers over their life times (Levine et al., 2006).
Given these observations one might have thought that the small DNA
tumor viruses would be the cause of wide spread cancers in humans.
For the Human Papilloma viruses there are some strains that cause
benign tumors (warts) and others that cause malignant cancers at
locations where the virus is transmitted (venereal cancers). Recently a
new human Polyomavirus has been found that is associated with a
rare Merkel cell cancer in humans (Feng et al., 2008). There are other
human Polyomaviruses, BK and JC, which are readily found in humans
(BK is very common), but have never been convincingly associated
with human cancers. Even SV40, which was introduced into the
human population from 1953 to 1961 with the Polio vaccine and was
known to have replicated in humans who formed antibodies against
this virus andwas secreted in the urine and feces, has not convincingly
been shown to be the cause of human cancers (but this is in dispute,
see below). Certainly the human Adenoviruses actively infect many
humans and do not appear to be associated with human cancers in
spite of their potent oncogenes. Why is this the case? How canwe live
so closely with the polyomaviruses and adenoviruses and not observe
them causing occasional cancers in humans?
There are several claims in the literature that the DNA from the
SV40 virus can be recovered by PCR from selected human tumors
(Klein et al., 2002). These tumors are papillomas of the choroid plexus
and mesotheliomas. There are several reasons to believe that these
observations represent virus contaminants of these tissues or viral
DNA's related to SV40 DNA sequences contaminating these tumors.
First when SV40 DNA causes a tumor it is found integrated into the
chromosome of all of the host cells of the tumor. This DNA expresses
the SV40 T-antigen in every cell of the tumor. The host responds by
producing antibodies to this foreign protein. These same observations
are not found in human tumors, rather very low levels of SV40 DNA
were detected in these tumors (less than onemolecule per cell) by PCR
and T-antigen was not detected in cells of the tumor. Thus our
understanding of how SV40 causes tumors completely fails to be
observed in human tumors. On the other hand if SV40 still persists in
human populations because of its introduction with the Polio vaccine
in 1953 to 1961 it might well be expected to replicate poorly in human
choroid plexus and kidneys (secreted in the urine). When SV40 DNA
was introduced into the germ line of mice, creating transgenic mice, it
produced tumors which were papillomas of the choroid plexus
(Brinster et al., 1984). This is because the SV40 enhancer DNA
sequences only express the SV40 T-antigen in this tissue of the
mouse (van Dyke et al., 1987) and so the choroid plexus contains those
transcription factors that recognize this enhancer element. The
choroid plexus is a tissue that produces cerebral–spinal ﬂuid and
ﬁlters molecules into and out of the central nervous system. Its
functions are related to the kidney where SV40 DNA also expresses
and replicates in monkeys and humans. Thus the choroid plexus
would be a good tissue for low levels of virus expression and
contamination. Clearly many of the patients with this tumor and
detectable SV40 DNA today, never received SV40 contaminated Polio
vaccine, so those DNA sequences detected in these tumors either
derive from a continued low level passage of SV40 in human
populations or a closely related human virus. In order for the SV40
virus to have caused these tumors it would have had to initiate thetumor and then it was no longer needed and was lost from the tumor.
This “hit and run” mechanism is contradicted by the observation that
tumors produced by the small DNA tumor viruses (including HPV
induced tumors in humans) require the viral DNA and tumor antigens
both for the initiation and the maintenance of these tumors. Thus it
seems unlikely that SV40 causes human cancers in a natural setting.
However several scientists who worked in the laboratory with very
large levels of SV40 viruses, at a time when few if any precautions
were taken to protect laboratory workers from the viruses they
worked with, developed cancers at young ages. When tissue sections
from these tumors were examined for SV40 DNA sequences using PCR
no evidence of such DNA sequences were detected (Howley et al.,
1991).
Similarly all attempts to detect Adenovirus DNA sequences
integrated into the chromosomes of human tumors have failed. This
is in spite of the fact that infectious Adenoviruses persists over long
time periods in lymphoid tissues and in epithelial tissues in many
humans. Even more puzzling is the fact that the Adenovirus DNA
packaging signals are closely associated with the Adenovirus E1A and
E1B genes in the viral chromosomes. This means that defective viruses
(which are common in virus preparations) that cannot replicate and
kill cells will almost always contain the viral oncogenes and yet these
viruses don't cause human cancers.
It appears likely that the natural history and properties of these
viruses in humans and the immunological response of the host might
prevent these tumors from arising (see Frazer, this volume). We know
very little of the role of the innate immune response to these viruses.
On the other hand both the B-cell and T-cell adaptive response is
vigorous (Tevethia et al., 1992; Schell et al., 1999). Benign Papilloma
viruses that cause warts in many locations all over the body can
undergo “spontaneous” remissions at all systemic locations simulta-
neously and that appears to be due to an immune response. The
adenoviruses persisting in lymphoid tissues (adenoids, tonsils) are
known to give rise to good T-cell responses. In the case of SV40 the
viral large T-antigen has amino acid sequences that act as a tumor
speciﬁc transplantation rejection antigen (Schell et al., 1999). Perhaps
our immune system plays a role in suppressing the ability of these
viruses to cause cancers in their natural hosts. However, in cases
where human hosts are immunosuppressed by HIV infection or tissue
transplants, viruses like Epstein Barr Virus and Kaposi sarcoma virus
can initiate cancers in humans, but we do not see the small DNA tumor
viruses playing a role in those types of cancers. At least based upon
these criteria the adaptive immune system does not explainwhy these
viruses are so poor at causing cancers in humans. There is still clearly a
need to better understand the role of the innate immune system in
protecting humans from viral induced cancers.
What questions remain in the study of the small DNA
tumor viruses?
This sixty year history of the small DNA tumor viruses and the role
they played in our understanding of cancers in humans has
demonstrated the value of fundamental scientiﬁc research and the
twists and turns that make science interesting and special. Like many
ﬁelds that are mature (phage research, bacterial genetics, etc) there
are now less scientists that study this topic and fewer students who
are entering this ﬁeld. Yet there remain many fundamental questions
that are unanswered. There is a third domain in the SV40 large
T-antigen gene (in addition to those binding p53 and Rb) that is
required for transformation and we only incompletely understand its
function (Pipas and Levine, 2001a,b; see Pipas, Roberts, Branton,
Galloway, Munger and DiMaio, this volume). The SV40 small t-antigen
is required for transformation of cells and while it is a subunit of the
PP2A phosphatase, we do not know its protein substrates or what it
does functionally. In addition to the Adenovirus E1A and E1B genes
several additional genes can play a role in transformation, especially in
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those mechanisms of action. There are suggestions in the literature
that the human Papilloma virus E6 and E7 genes have functions in
addition to those of inactivating p53 and Rb. Some Papilloma viruses
employ the E5 protein for transformation through a different
mechanism. It is likely that there are more polyomaviruses and
papilloma viruses to be found in humans as well as novel Adeno-
viruses with new properties, maybe even tumorigenic properties. Just
how these viruses persist in their hosts, even in the face of an immune
response, remains to be understood. Are these viruses activated by
stress signals, hormonal signals, other infectious agents or immuno-
suppression? At what rate do these viruses evolve in human
populations? Are recombinant viruses a common feature within
each virus group or even between virus groups? Are these viruses
evolving more rapidly in hosts with poor immune systems? What
determines the cell type speciﬁcity of these viruses; cell adsorption,
the transcriptional enhancer elements in the DNA, the ability of the
virus to initiate a new round of DNA replication in the host cell, and/or
other properties of these agents? Can these viruses be employed
efﬁciently in gene therapy or in vaccine development for other
agents? These are but a few of the avenues to be explored in the
research of the future, if only young virologists see the potential of
these agents to answer important questions.
The new technologies; transcriptional proﬁling, characterization of
genetic polymorphisms (both single nucleotide polymorphisms and
copy number variations) in the host and the virus, deep and high
volume DNA sequencing, quantifying the immune system of the host
in response to a virus infection, sensitive detection (PCR) of low levels
of persistent viruses in the host and changes over time and following
the spread of the virus in populations, nowmake it possible to explore
human hosts and their DNA tumor viruses. Perhaps this is the new
ﬁeld for the future virologists and the human is the new experimental
animal of choice for these studies. If Maurice Hilleman, Wally Rowe
and Bernice Eddy were just starting their careers today, they might
well ﬁnd some of these questions and challenges irresistible.
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